Donald Trump expected to fire head of Food and Drug Administration - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
FT商学院

Donald Trump expected to fire head of Food and Drug Administration

Marty Makary had clashed with anti-abortion advocates and is the latest top health official to lose their job
00:00

{"text":[[{"start":8.5,"text":"President Donald Trump is expected to fire Marty Makary, the head of the US Food and Drug Administration, according to people familiar with the matter, adding to turbulence at the medicines regulator and throwing into doubt drug approvals for the biotech industry."}],[{"start":23.85,"text":"The White House was on Friday searching for a replacement for Makary, the people said. The White House and FDA declined to comment. Asked by reporters on Friday night if he intended to fire Makary, Trump said: “I’ve been reading about it, but I know nothing about it.”"}],[{"start":40.3,"text":"In recent days, Makary has come under pressure from anti-abortion advocates, a crucial voting bloc for Trump in the forthcoming midterm elections. Makary’s expected firing was in part because of the FDA’s positions on abortion pills, people in Washington said on Friday. The Susan B Anthony anti-abortion advocacy group on Monday said Makary “should be fired immediately”."}],[{"start":64.69999999999999,"text":"The FDA continues to say the abortion pill mifepristone is safe, while anti-abortion groups argue it is dangerous for women’s health. Anti-abortion advocates were scheduled to meet Trump officials at the White House on Friday."}],[{"start":77.44999999999999,"text":"Shares of biotech companies were little changed on Friday after The Wall Street Journal first reported that Makary was being pushed out. But Hims & Hers, a telehealth company that has drawn fire from the FDA for compounding drugs, increased 10 per cent."}],[{"start":93.35,"text":"Makary’s expected firing is the latest in a series of personnel changes at Trump’s health regulators. In August, Trump sacked the head of the Centers for Disease Control and Prevention. Earlier in 2025, health secretary Robert F Kennedy Jr removed all 17 members of a top vaccine advisory committee."}],[{"start":112.44999999999999,"text":"A surgeon from Johns Hopkins Hospital in Baltimore, Makary initially won applause from Trump’s allies for criticising what he called the silencing of critics of the Covid-19 vaccines."}],[{"start":124.35,"text":"“The way that any dissenting opinion was silenced, crushed, sidelined, railroaded, that was remarkable to me,” Makary said at a Stanford University event in 2024."}],[{"start":136.6,"text":"After starting at the FDA in April 2025, Makary was quickly hit by staff cuts at the agency as Elon Musk’s efforts to shrink the size of the federal government advanced across Washington. Makary also faced controversy over his deputy at the FDA, Vinay Prasad, a vocal Covid-19 vaccine sceptic."}],[{"start":157.1,"text":"Prasad last year claimed without evidence that Covid vaccines killed at least 10 children. This year, he refused to consider Moderna’s new flu vaccine for FDA approval, criticising the design of scientific trials that the agency had previously agreed. Days later, Makary was summoned to the White House, and the regulator reversed its decision against Moderna."}],[{"start":178,"text":"Makary’s expected firing is likely to sow confusion for the maker of pharmaceutical drugs hoping to win FDA approvals."}],[{"start":186.15,"text":"The FDA regulates drugs in the US, the world’s largest pharmaceutical market. The agency’s decisions on medicines are widely watched by drug regulators across the world and have multimillion-dollar implications for biotech businesses."}],[{"start":200.05,"text":"Trump’s decision to fire Makary “would not be particularly surprising given clashes with Makary and the Trump administration”, Evan Seigerman, an analyst with BMO Capital Markets, said in a report on Friday. "}],[{"start":212.10000000000002,"text":"“If Makary is ultimately removed, we would view this as a broad positive for the sector, potentially bringing more consistency to messaging, incentivising further investment.”"}],[{"start":228.60000000000002,"text":""}]],"url":"https://audio.ftcn.net.cn/album/a_1778309610_4475.mp3"}

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

高盛击败大摩金牌顾问,斩获SpaceX上市第一大单

这位知名科技投行家在特朗普政府任职期间,失去了对马斯克这桩重磅上市交易的影响力

现代战争的血腥一如往昔

科技的进步并没有减少俄乌战争中的伤亡,武装无人机和AI正把前线变成险恶的杀戮地带,惨烈程度堪比一战。

帕拉贝利斯医药公司于与再生元达成交易次日披露IPO计划,上市热潮升温

成立已有十年且资金雄厚、从格雷格•维尔丁在哈佛实验室孵化出的“不可成药”生物技术公司——帕拉贝利斯医药公司,正寻求成为今年第12家进行首次公开募股的药物研发企业
22小时前

英伟达部署900亿美元助推AI繁荣

黄仁勋正成为依赖其芯片的AI相关公司的最大资助者之一。这些支出涉及逾145家公司,从AI模型开发商、云服务提供商到基础设施供应商不一而足。

Lex专栏:股市投资者信心爆棚,但现金见底

鉴于标普500指数高度依赖以人工智能为驱动的公司,股市出现小问题和大问题的可能性都很大。

FT社评:埃博拉疫情暴露全球应对大流行病准备不足

援助资金减少以及特朗普政府对全球公共卫生理念的敌意,正危及我们所有人。
设置字号×
最小
较小
默认
较大
最大
分享×